Filed: 5/15/2025ACC: 0001104659-25-049390
📋 What this filing means
FORESITE CAPITAL MANAGEMENT IV, LLC filed this quarterly 13F‑HR report disclosing 5 equity positions with a total reported market value of $111.07M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
5
Positions
$111.07M
Total AUM (reported)
24.64M
Total Shares
Allocation by class
COM$111.07M100.0%
Portfolio Concentration
Top 3$101.11M91.0%
4–10$9.96M9.0%
Top 3 weight
91.0%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 24.64M
Sole
Full voting authority
24.64M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole5
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings5
Rows:
Pharvaris N.V.
SOLEShares4.41M
TypeSH
Market value$69.25M
62.35%
Sole
4.41M
Shared
0.00
None
0.00
Maze Therapeutics Inc
SOLEShares2.11M
TypeSH
Market value$23.25M
20.93%
Sole
2.11M
Shared
0.00
None
0.00
Lyell Immunopharma, Inc.
SOLEShares16.01M
TypeSH
Market value$8.61M
7.75%
Sole
16.01M
Shared
0.00
None
0.00
Kura Oncology, Inc.
SOLEShares1.11M
TypeSH
Market value$7.34M
6.61%
Sole
1.11M
Shared
0.00
None
0.00
Relay Therapeutics Inc.
SOLEShares1M
TypeSH
Market value$2.62M
2.36%
Sole
1M
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Pharvaris N.V.SOLE | COM | 4.41M | SH | $69.25M 62.35% | 4.41M | 0.00 | 0.00 |
Maze Therapeutics IncSOLE | COM | 2.11M | SH | $23.25M 20.93% | 2.11M | 0.00 | 0.00 |
Lyell Immunopharma, Inc.SOLE | COM | 16.01M | SH | $8.61M 7.75% | 16.01M | 0.00 | 0.00 |
Kura Oncology, Inc.SOLE | COM | 1.11M | SH | $7.34M 6.61% | 1.11M | 0.00 | 0.00 |
Relay Therapeutics Inc.SOLE | COM | 1M | SH | $2.62M 2.36% | 1M | 0.00 | 0.00 |